Psoriasis Treatment Market Insight Estimated Size To Experience Significant Growth By 2030

Comments · 291 Views

Rising treatment awareness and improved healthcare infrastructure are anticipated to have a significant positive impact on the market for psoriasis treatments in 2023.

Psoriasis treatment market insights and analysis by drug class, treatment type by topicals - forecast till 2030

As per the analysis by Market Research Future Reports (MRFR), the global psoriasis treatment market is anticipated to garner the market value of USD 48.33 billion, expanding at a CAGR of 7.8% during the assessment period from 2022 to 2030.

Environmental and genetic factors are thought to play a role in the development of the psoriasis illness. Rising treatment awareness and improved healthcare infrastructure are anticipated to have a significant positive impact on the market for psoriasis treatments in 2023. Other important aspects boosting the global market include the adoption of a sedentary lifestyle, rising alcohol consumption, smoking, and a poor diet. Additionally, the market has grown as a result of the rise in psoriasis instances brought on by the increased exposure to chemicals and pollutants.

Contrarily, it is predicted that the high expenses associated will impede market expansion during the review period. However, it is anticipated that the market for psoriasis treatments would increase significantly due to the rising use of alternative psoriasis therapies and the ongoing competition among the major players.

Key Players

The renowned global psoriasis treatment market players are UCB (Belgium), Novartis International AG (Switzerland), AstraZeneca (UK), Johnson Johnson (US), Celgene Corporation (US), Pfizer Inc (US), AbbVie (US), Merck and Co. Inc (US), Amgen (US), and Eli Lilly and Company (US).

Market Segmentation

The segment evaluation of the global psoriasis treatment market trend is done by treatment type and drug class.

The global market for psoriasis treatment, by drug class, is segmented into Interleukin-inhibitors, tumor necrosis factor inhibitors, and vitamin D analogs. Moreover, tumor necrosis factor inhibitors are segmented into infliximab, adalimumab, and etanercept. Furthermore, Interleukin-inhibitors is segmented into secukinumab, ustekinumab, ixekizumab, and brodalumab. Vitamin D analogs are segmented into calcipotriol, calcitriol, and tacalcitol.

The global market for psoriasis treatment, by treatment, is segmented into systemic, topicals, and biologics. Topicals are further segmented into topical non-steroid, over the counter (OTC) topicals, topical steroids. Systemic is segmented into cyclosporine, retinoid, and methotrexate. Biologics is sub-segmented into InterleU.K.in 12, and 23 (IL-12/23) inhibitors, tumour necrosis factor-alpha (TNF-a) inhibitors, InterleU.K.in 17 (IL-17) inhibitor, and T cell inhibitor.

Regional Analysis

Based on the region, the global psoriasis treatment market is segmented into the Americas, Asia-Pacific. Europe, and the Middle East and Africa.

As per the analysis, the global market is projected to be dominated by the Americas. The region is estimated to flourish owing to the increased awareness, rising patient pool, and the presence of established key players. According to a recent study, more than 8 million Americans are estimated to have been infected with psoriasis, with the US reporting 150,000 cases every year. In North America, the US and Canada are predicted to make the most significant contribution in boosting the regional market in the forthcoming period.

Europe is likely to obtain a second position by acquiring the second largest market share. The regional market is flourishing owing to the increased awareness about the ailment and the growing demand for an efficient treatment. Further, the rise in RD activities to produce a long-term solution to the disease is likely to be another crucial factor in boosting the regional market.

The APAC region, on the other hand, is considered to have the fastest market growth due to the presence of a developing nation and its emphasis on expanding the healthcare infrastructure. It is anticipated that developing nations like India, China, and Japan will accelerate market growth by significantly funding research and development..

The MEA region is anticipated to acquire the least market share during the review period owing to the presence of underdeveloped economies and lack of awareness.

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Contact Us:

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: [email protected]

Website: https://www.marketresearchfuture.com

Comments